Drug Type Small molecule drug |
Synonyms |
Mechanism BTK C481S inhibitors(Bruton Tyrosine Kinase C481S inhibitors), BTK inhibitors(Tyrosine-protein kinase BTK inhibitors), Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Malignant Neoplasm | Preclinical | CN | 27 Dec 2023 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Preclinical | CN | 27 Dec 2023 | |
Rheumatoid Arthritis | Preclinical | CN | 27 Dec 2023 | |
Lymphoma | Preclinical | CN | 17 Apr 2023 | |
B-Cell Leukemia | Preclinical | CN | 04 Apr 2023 |